Bioversys N
Clinical-stage biopharma developing antibacterial therapies for antimicrobial resistance.
BIOV | SW
Overview
Corporate Details
- ISIN(s):
- CH0210362643 (+1 more)
- LEI:
- 894500UFIGC75NPZEZ68
- Country:
- Switzerland
- Address:
- Hochbergerstrasse 60C, 4057 Basel
- Website:
- https://www.bioversys.com/
- Sector:
- Manufacturing
Description
Bioversys is a clinical-stage biopharmaceutical company focused on the research and development of novel antibacterial therapies to combat the global threat of antimicrobial resistance (AMR). The company develops small molecule drugs that act on novel bacterial targets through innovative modes of action. Its clinical pipeline includes BV100, a treatment for serious hospital infections caused by Acinetobacter baumannii, and Alpibectir, a novel potentiator for multidrug-resistant tuberculosis (MDR-TB). Both candidates are in Phase 2 clinical development. The company's earlier-stage portfolio includes BV200, an anti-virulence compound for Staphylococcus aureus infections, and BV500 for Nontuberculous mycobacteria (NTM) infections, addressing critical unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-11 07:00 |
BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update
|
English | 22.0 KB | ||
| 2025-12-11 01:00 |
BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update
|
English | 16.0 KB | ||
| 2025-11-10 07:00 |
BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network
|
English | 26.0 KB | ||
| 2025-11-10 01:00 |
BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network
|
English | 19.5 KB | ||
| 2025-11-06 07:00 |
Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in …
|
English | 13.1 KB | ||
| 2025-11-06 01:00 |
Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in …
|
English | 12.1 KB | ||
| 2025-11-05 07:00 |
Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york
|
English | 6.9 KB | ||
| 2025-11-05 01:00 |
Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york
|
English | 5.6 KB | ||
| 2025-11-03 07:00 |
Bioversys announces appointment of anti-infective expert Dr. Daniel Ritz as Chi…
|
English | 9.0 KB | ||
| 2025-11-03 01:00 |
Bioversys announces appointment of anti-infective expert Dr. Daniel Ritz as Chi…
|
English | 7.9 KB | ||
| 2025-09-10 07:00 |
Bioversys reports corporate highlights and key financials for the first half 20…
|
English | 24.8 KB | ||
| 2025-09-10 02:00 |
Bioversys reports corporate highlights and key financials for the first half 20…
|
English | 23.3 KB | ||
| 2025-09-10 00:00 |
BioVersys Half Year Report 2025
|
English | 1.8 MB | ||
| 2025-08-27 07:00 |
BioVersys receives EMA Orphan Designation for the combination of alpibectir and…
|
English | 21.9 KB | ||
| 2025-08-27 02:00 |
BioVersys receives EMA Orphan Designation for the combination of alpibectir and…
|
English | 15.9 KB |
Automate Your Workflow. Get a real-time feed of all Bioversys N filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Bioversys N
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Bioversys N via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
